$DARE was illiquid before this financing -- its first since DARE has been on NASDAQ. Now it is quite possible that $DARE will finally trade like a very low-float ticker. Having the license to the "woman's Viagra" will give it a strong push at some point, and while the non-hormonal contraceptive lacks some pizazz, it is definitely a need for the market.
Perhaps I speak more from hope than fact, but it will erupt hard at some point now, as it has a ew sort of investor now -- the ones that like to make biotechs go from way undervalued to way overvalued in the space of a few trading days.
News 
Market Data 
Discover 
